The Journal of Evidence-Based Dental Practice Focuses on Periodontal and Implant Treatments

First in new 'Annual Report' series provides essential updates on evidence-based care in periodontics and implant dentistry

St. Louis, MO, October 2, 2012 – What's the latest, research-supported best practice in periodontal care and implant dentistry? Dental specialists and generalists alike can read about it in the first of a new series from The Journal of Evidence-Based Dental Practice (JEBDP), the foremost publication of information about evidence-based dental practice, published by Elsevier.

The inaugural edition of the Annual Report on Periodontal and Implant Treatment is now available, containing concise, authoritative reviews based on the evidence about practice-critical topics. Mark A. Reynolds, DDS, PhD, Professor, Chair, and Director of Postgraduate Periodontics at University of Maryland School of Dentistry, Baltimore, is editor of the new Annual Report on Periodontal and Implant Treatment.

"Advances in periodontics and implant dentistry continue at an unprecedented pace, with an overwhelming number of new publications each month," commented Dr. Reynolds. "The goal of the Annual Report is to help promote excellence in patient care by providing dentists and other health care professionals with concise, evidence-based reviews on timely topics in periodontics and implant dentistry."

The Annual Report presents 18 focused reviews, contributed by leading dental academicians and clinicians from across the United States and Europe. Reviews are organized into the categories of:

In addition to the original articles, the Annual Report contains over 20 previously published Article Analysis and Reviews from past issues of the JEBDP. Written by a diverse interdisciplinary group of world-renowned authors, these past reviews were selected to supplement the topics discussed in the original articles.

The information will be of high value not only to periodontists, prosthodontists, and oral and maxillofacial surgeons, but also to the broader group of general dental practitioners and dental hygienists involved in treating patients with or at risk of periodontal and peri-implant disease. "Our Annual Report fulfills the need for a conduit of information on the current state of evidence," Dr. Reynolds added. "Such an update is critical for assisting time-pressured practitioners in expanding their knowledge and enhancing their effectiveness in patient care."

The special edition is part of a new series of Annual Reports devoted to concise reviews on important topics in specific areas. "TheAR series will provide the dental and medical community with an authoritative, time-saving, unbiased, and objective assessment of various treatments," commented Michael G. Newman, DDS, Professor Emeritus at the UCLA School of Dentistry and Editor-in-Chief of JEBDP. "We believe that the AR's highly illustrated, short, authoritative, and critical summaries of the latest research are the best way to reach busy clinicians."

The JEBDP Annual Report on Periodontal and Implant Treatment is supported by educational grants from Nobel Biocare, Colgate, Straumann, Geistlich North America, Organogenesis, and Medtronic. Every dental school and all oral surgery and periodontal residents in the United States will receive copies of the Annual Report.

To order the Annual Report, visit  http://www.jebdp.com and follow the link. For bulk sales, please contact Jane Ryley at the e-mail address or phone number shown above.

# # #

Notes for editors
The Journal of Evidence-Based Dental Practice Annual Report on Periodontal and Implant Treatment is published by Elsevier. For full texts of articles published in the issue or for further information about JEBDP please contact j.ryley@elsevier.com at +1 314 447 9226; or visit:  www.jebdp.com.

About The Journal of Evidence-Based Dental Practice
The Journal of Evidence-Based Dental Practice (JEBDP) presents timely original articles, as well as reviews of articles on the results and outcomes of clinical procedures and treatment. The journal advocates the use or rejection of a procedure based on solid, clinical evidence found in literature. The journal's dynamic operating principles are explicitness in process and objectives, publication of the highest-quality reviews and original articles, and an emphasis on objectivity. Visit the journal website at  www.jebdp.com.

About Elsevier 
Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including  The Lancet and  Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier’s online solutions include  ScienceDirect Scopus Reaxys ClinicalKey and  Mosby’s Nursing Suite, which enhance the productivity of science and health professionals, and the  SciVal suite and  MEDai’s Pinpoint Review, which help research and health care institutions deliver better outcomes more cost-effectively.

A global business headquartered in Amsterdam,  Elsevier employs 7,000 people worldwide. The company is part of  Reed Elsevier Group PLC, a world-leading publisher and information provider, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

About Elsevier

Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence,and ClinicalKey—and publishes over 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.

The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

Media contact
Jane Ryley
Elsevier
+1 314 447 9226
jane.ryley@elsevier.com